{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:43:33Z","timestamp":1782927813664,"version":"3.54.5"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Immune Checkpoint Inhibitors (ICI) are nowadays a cornerstone of anti-cancer treatments. However, the wide spectrum of immune-related adverse events (irAEs) represents a challenge in the oncological practice. Our objective is to document rare complications of ICI to help the community of onco-immunologists.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We reported the case of a severe myositis mimicking bulbar palsy treated in our Medical Oncology Department together with Internal Medicine Department. We present the clinical work-up (neurological exam, capillaroscopy) and the diagnostic tests (myositis specific and associated antibodies, nerve conduction study, electromyography) leading to this diagnosis. We also discussed the elimination of differential diagnoses (notably with normal MRI and cerebrospinal fluid analysis) and finally the clinical management of this severe irAE.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A 57 years woman presented multiple sub-diaphragmatic adenopathies related with an advanced melanoma of unknown primary. She started a treatment with Ipilimumab (Ipi, anti CTLA-4) and Nivolumab (Nivo, anti PD-1) and presented at day 10 a grade IV myositis mimicking bulbar palsy with dysphonia, dysarthria and aphagia. In a multidisciplinary setting, she was treated with IV corticosteroids (methylprednisolone 1 mg\/kg started at day 10, with a progressive decrease until 1 mg of prednisone in March 2024), IV immunoglobulins started at day 18 (1.5 g\/kg in 2 days, administered monthly, with a progressive decrease and a cessation in June 2022), enteral nutrition, speech therapy and physical therapy, with noticeable improvement. After 4 years of follow-up, and only one infusion of Ipi\/Nivo, the melanoma is still in complete response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We report an ICI-induced severe myositis mimicking bulbar palsy after the administration of Ipi\/Nivo. The diagnosis and clinical care management of this rare complication requires a multi-disciplinary work-up.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1496427","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T06:48:51Z","timestamp":1739170131000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Case report: A severe myositis mimicking bulbar palsy after administration of immune checkpoint inhibitors"],"prefix":"10.3389","volume":"16","author":[{"given":"Philippe","family":"Rochigneux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Bertucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elika","family":"Loir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Mattei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brice","family":"Chanez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Ebbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Gaigne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Sophie","family":"Chretien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Corazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Schleinitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04710-2","article-title":"Nailfold videocapillaroscopy alterations in dermatomyositis, antisynthetase syndrome, overlap myositis, and immune-mediated necrotizing myopathy","volume":"38","author":"Soubrier","year":"2019","journal-title":"Clin Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1991.00530170061021","article-title":"Acute pseudobulbar or suprabulbar palsy","volume":"48","author":"Besson","year":"1991","journal-title":"Arch Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.123.046122","article-title":"Effect of intermittent oro-esophageal tube feeding in bulbar palsy after ischemic stroke: A randomized controlled study","volume":"55","author":"Zeng","year":"2024","journal-title":"Stroke"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/BF01324832","article-title":"Chronic lymphocytic leukemia with CNS involvement","volume":"16","author":"Pohar","year":"1993","journal-title":"J Neurooncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20272","article-title":"Leptomeningeal disease: current diagnostic and therapeutic strategies","volume":"8","author":"Nayar","year":"2017","journal-title":"Oncotarget"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011795","article-title":"Neurologic adverse events of immune checkpoint inhibitors: A systematic review","volume":"96","author":"Marini","year":"2021","journal-title":"Neurology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2023.03.003","article-title":"Neurological adverse events of immune checkpoint inhibitors: An update of clinical presentations, diagnosis, and management","volume":"179","author":"Farina","year":"2023","journal-title":"Rev Neurol (Paris)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25141","article-title":"Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab","volume":"54","author":"Lau","year":"2016","journal-title":"Muscle Nerve"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.64.10.1519","article-title":"Continuous spectrum of pharyngeal-cervical-brachial variant of Guillain-Barr\u00e9 Syndrome","volume":"64","author":"Nagashima","year":"2007","journal-title":"Arch Neurol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13256-022-03290-1","article-title":"Mononeuritis multiplex as a rare and severe neurological complication of immune checkpoint inhibitors: a case report","volume":"16","author":"Abdelhakim","year":"2022","journal-title":"J Med Case Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1338899","article-title":"Mononeuritis multiplex following immune checkpoint inhibitors in Malignant pleural mesothelioma","volume":"15","author":"Farina","year":"2024","journal-title":"Front Neurol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","article-title":"Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors","volume":"106","author":"Moreira","year":"2019","journal-title":"Eur J Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006124","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer","volume":"91","author":"Touat","year":"2018","journal-title":"Neurology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"100791","DOI":"10.1016\/j.esmoop.2023.100791","article-title":"Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature","volume":"8","author":"Boutros","year":"2023","journal-title":"ESMO Open"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-12134-x","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series","volume":"271","author":"Vicino","year":"2024","journal-title":"J Neurol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcaa181","article-title":"Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy","volume":"2","author":"Shelly","year":"2020","journal-title":"Brain Commun"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw655","article-title":"Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm","volume":"28","author":"Haddox","year":"2017","journal-title":"Ann Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2021.03.005","article-title":"Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome","volume":"46","author":"Lipe","year":"2021","journal-title":"Am J Emerg Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100317","article-title":"How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors","volume":"6","author":"Jordan","year":"2021","journal-title":"ESMO Open"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1431971","article-title":"Management of overlapping immune-related myocarditis, myositis, and myasthenia in a young patient with advanced NSCLC: a case report","volume":"14","author":"Mariniello","year":"2024","journal-title":"Front Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.08.048","article-title":"The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry","volume":"158","author":"Ruste","year":"2021","journal-title":"Eur J Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1496427\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T06:48:53Z","timestamp":1739170133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1496427\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":21,"alternative-id":["10.3389\/fimmu.2025.1496427"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1496427","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]},"article-number":"1496427"}}